$154 Million is the total value of Athyrium Capital Management, LP's 7 reported holdings in Q2 2023. The portfolio turnover from Q1 2023 to Q2 2023 was 12.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| Biora Inc.note 7.250% 12/0 | $60,477,148 | +4.1% | 103,500,000 | 0.0% | 39.23% | +88.6% | ||
| Buy | Omeros Corpnote 5.250% 2/1 | $52,755,389 | +13.4% | 71,979,000 | +10.5% | 34.22% | +105.4% | |
| Omeros Corpnote 6.250%11/1 | $11,037,382 | -0.7% | 11,005,000 | 0.0% | 7.16% | +79.9% | ||
| Paratek Pharmaceuticals Inc.note 4.750% 5/0 | $8,848,843 | +19.3% | 9,000,000 | 0.0% | 5.74% | +116.1% | ||
| OSMT | RVL PHARMACEUTICALS PLC | $8,177,709 | -50.9% | 14,600,444 | 0.0% | 5.30% | -11.0% | |
| Biora Inc. | $6,523,751 | +39.0% | 1,694,481 | 0.0% | 4.23% | +151.6% | ||
| PBYI | PUMA BIOTECHNOLOGY INC | $6,326,162 | +14.2% | 1,792,114 | 0.0% | 4.10% | +106.9% | |
| AMYT | Exit | Amryt Pharma PLCsponsored ads | $0 | – | -8,857,268 | -100.0% | -46.27% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-08-14
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Amryt Pharma PLC | 10 | Q1 2023 | 46.3% |
| Progenity Inc. | 9 | Q4 2022 | 69.2% |
| Progenity Inc. | 8 | Q3 2023 | 39.2% |
| RVL PHARMACEUTICALS PLC | 8 | Q3 2023 | 11.5% |
| Societal CDMO Inc. | 8 | Q4 2022 | 3.1% |
| Omeros Corp | 7 | Q3 2023 | 39.3% |
| CAREMAX INC | 7 | Q4 2022 | 27.5% |
| Omeros Corp | 7 | Q3 2023 | 9.9% |
| PUMA BIOTECHNOLOGY INC | 7 | Q3 2023 | 4.2% |
| AEGERION PHARMACEUTICALS INC | 6 | Q1 2019 | 88.7% |
View Athyrium Capital Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| PROGENITY, INC. | August 27, 2021 | 4,211,977 | 2.7% |
View Athyrium Capital Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR/A | 2023-05-16 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
View Athyrium Capital Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.